Abhirami Babu

Ms. Abhirami Babu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AGAman Goyal
Aman Goyal
MKMichail Koutentakis
Michail Koutentakis
Jason J ParkJason J Park
Jason J Park
Christian Adrian Macias ArguelloChristian Adrian Macias Arguello
Christian Adrian Macias Arguello
IBIsaac Ballard
Isaac Ballard
RORodolfo J Oviedo
Rodolfo J Oviedo
Background: Hepatopancreatobiliary (HPB) surgery is among the most complex domains in oncologic care, where decisions entail significant risk–benefit considerations. Artificial intelligence (AI) has emerged as a promising tool for improving individualized decision-making through enhanced risk stratification, complication prediction, and survival modeling. However, its role in HPB oncologic surgery has not been comprehensively assessed. Methods: This systematic review was conducted in accordance with PRISMA guidelines and registered with PROSPERO ID: CRD420251114173. A comprehensive search across six databases was performed through 30 May 2025. Eligible studies evaluated AI applications in risk–benefit assessment in HPB cancer surgery. Inclusion criteria encompassed peer-reviewed, English-language studies involving human s ubjects. Two independent reviewers conducted study selection, data extraction, and quality appraisal. Results: Thirteen studies published between 2020 and 2024 met the inclusion criteria. Most studies employed retrospective designs with sample sizes ranging from small institutional cohorts to large national databases. AI models were developed for cancer risk prediction (n = 9), postoperative complication modeling (n = 4), and survival prediction (n = 3). Common algorithms included Random Forest, XGBoost, Decision Trees, Artificial Neural Networks, and Transformer-based models. While internal performance metrics were generally favorable, external validation was reported in only five studies, and calibration metrics were often lacking. Integration into clinical workflows was described in just two studies. No study addressed cost-effectiveness or patient perspectives. Overall risk of bias was moderate to high, primarily due to retrospective designs and incomplete reporting. Conclusions: AI demonstrates early promise in augmenting risk–benefit assessment for HPB oncologic surgery, particularly in predictive modeling. However, its clinical utility remains limited by methodological weaknesses and a lack of real-world integration. Future research should focus on prospective, multicenter validation, standardized reporting, clinical implementation, cost-effectiveness analysis, and the incorporation of patient-centered outcomes.

26 June 2025
Verified
Book Chapter
Open access
PDF file
RBRaghav Bansal
Raghav Bansal
PJPalak Kirti Jain
Palak Kirti Jain
ABAbhirami Babu
Abhirami Babu
VKVedant Sachin Kasmalkar
Vedant Sachin Kasmalkar
SMSamridhi Mahajan
Samridhi Mahajan
This chapter provides a comprehensive overview of choledocholithiasis (common bile duct stones), focusing on its introduction, etiology, pathogenesis, epidemiology, clinical presentation, and diagnostic modalities. With the evolution of treatment strategies, it highlights the paradigm shift in managing choledocholithiasis, particularly the growing preference for laparoscopic common bile duct exploration (LCBDE) over endoscopic retrograde cholangiopancreatography (ERCP). While ERCP has long been the standard of care, its limitations seen in failed or complex cases have catalyzed the adoption of LCBDE, especially in regions where advanced ERCP resources are limited. Further, it delves into the emerging trends, emphasizing LCBDE’s advantages as a single-stage, cost-effective approach that reduces the need for multiple interventions and addresses challenges raised by ductal clearance. It examines regional variations in the adoption of treatment modalities, with LCBDE being more prevalent in the Indian subcontinent due to unique demographic and healthcare system constraints. Furthermore, the chapter critically evaluates procedural outcomes, patient safety, and the role of technological advancements—such as laparoscopic ultrasound and robotic assistance—in enhancing surgical precision and efficacy. By presenting evidence-based insights and practical considerations, this chapter aligns with the broader theme of advancing surgical education and innovation, as explored in Upper Gastrointestinal Surgery – Contemporary Techniques and Training. It aims to equip surgeons, trainees, and multidisciplinary teams with the knowledge and tools necessary to harness modern techniques like LCBDE for optimal patient outcomes. Ultimately, the chapter underscores how emerging trends in choledocholithiasis management reflect a commitment to improving procedural efficiency, minimizing complications, and addressing the evolving challenges in global healthcare.


1 January 2026 in Intelligent Surgery
Verified
Journal Article
Open access
MKMichail Koutentakis
Michail Koutentakis
YPYuvraj G. Parmar
Yuvraj G. Parmar
ABAbhirami Babu
Abhirami Babu
VVVanessa Pamela Salolin Vargas
Vanessa Pamela Salolin Vargas
CBCarlos Felipe Bustillos
Carlos Felipe Bustillos
RORodolfo J Oviedo
Rodolfo J Oviedo

22 May 2026 in Medicine
Verified
Journal Article
Open access
OAONYEKACHI EMMANUEL Vision University ANYAGWA
ONYEKACHI EMMANUEL Vision University ANYAGWA
HSHashim Mohamed Siraj
Hashim Mohamed Siraj
HZHanzala Zahid
Hanzala Zahid
ODOluwatoyin Adalia Dairo
Oluwatoyin Adalia Dairo
MAMuhammad Husnain Ahmad
Muhammad Husnain Ahmad
CNChinedu Elvis Nwaduru
Chinedu Elvis Nwaduru
To characterize mortality trends associated with nontraumatic intestinal perforation (NIP) in the United States, which continue to remain poorly defined. NIP is defined as the loss of continuity of the bowel wall in which external trauma as an etiology has been excluded. NIP is a serious gastrointestinal emergency with limited national mortality trend data, particularly across various demographic and regional subgroups. NIP-related mortality data were extracted from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research database from 1999 to 2020. We analyzed age-adjusted mortality rates (AAMR) per 100,000 individuals and annual percent change (APCs) with 95% confidence interval (CI) in patients ≥ 15 years based on gender, race and geographical region. Overall, there were 122,161 NIP-related deaths among patients aged ≥ 15 years, with an increase in AAMR from 1.90 in 1999 to 2.0 in 2009 (APC: 0.19; CI: −0.33 to 0.71), and a gradual increase to 2.40 in 2020 (APC: 1.26; CI: 0.80 to 1.71). AAMR was lower in females compared to males in 1999 (2.0 vs 1.90; CI: 1.90 to 2.0). However, in 2020, AAMR values increased in females (2.20 vs 2.0; CI: 2.40 to 2.60; P < .05). AAMRs were higher in patients reported as non-Hispanic compared to Hispanic/Latinos (2.10 vs 1.50; CI: 2.10 to 2.10; P < .05). Variation in AAMR values across census regions was not significant. NIP-related AAMR was higher in nonmetropolitan than metropolitan areas (2.90 vs 1.90; CI: 2.10 to 2.10; P < .05). NIP-related mortality has risen among patients’ ≥15 years. Higher AAMRs in females, non-Hispanic individuals, and nonmetropolitan populations highlight the need for targeted preventive efforts.

9 October 2026 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
Christian Adrian Macias ArguelloChristian Adrian Macias Arguello
Christian Adrian Macias Arguello
AGAman Goyal
Aman Goyal
PCPhillip Chehet
Phillip Chehet
FMFederico Maria Mongardini
Federico Maria Mongardini
NZNicolas Zucchini
Nicolas Zucchini
RORodolfo J Oviedo
Rodolfo J Oviedo
Background: Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are considered major causes of cancer-related mortality. Evidence suggests that gut microbiome dysbiosis and the microbial–metabolic axis and its metabolites in hepatic chronic inflammation might be implicated in carcinogenesis in the gut–liver axis. This descriptive systematic review examines the microbial–metabolic axis in hepatobiliary cancer, focusing on patterns of dysbiosis, microbiome-associated metabolites, and the diagnostic or prognostic potential in this field. Methods: This manuscript was developed according to PRISMA 2020 guidelines and registered in PROSPERO (CRD420261455009). PubMed, Scopus, Cochrane Library, Web of Science, and Embase were searched. Eligible studies were published medical manuscripts reporting gut (oral/duodenal/fecal) microbiome alterations with links to HCC or CCA. Risk of bias was assessed with Rob 2.0 for the randomized clinical trial study included in this manuscript and ROBINS-I for the non-randomized studies. Ultimately, 13 studies met the inclusion criteria and were included in this qualitative study. Results: In the included studies, patients with HCC or CCA showed altered gut microbial diversity, a depletion of beneficial taxa such as Faecalibacterium and Bifidobacterium, and increased levels of potentially pro-inflammatory genera. Specific signatures such as Alloprevotella and the B.F.R. genera models in CCA were associated with diagnostic performance, with AUCs that frequently exceeded 0.90 in internal validation. Furthermore, circulating and host microbial metabolites, such as methionine, methionine sulfoxide, taurocholic acid, and microbial-derived TMA/TMAO pathway components, were associated with HCC risk. Conclusions: According to our analysis, gut microbiome alterations are associated with HCC and CCA and show promising diagnostic and prognostic potential. The findings are consistent with a possible microbial–metabolic contribution to hepatocarcinogenesis through chronic inflammatory and metabolic pathways. However, most included studies evaluated virus-related liver disease, and direct evidence linking obesity or MASLD-related dysbiosis to hepatobiliary cancer remains limited. Prospective and interventional investigations of metabolic liver disease populations are needed to clarify this axis.